Special Issue "Targeted Therapy of Hepatocellular Carcinoma: Present and Future"

Quicklinks

A special issue of Diseases (ISSN 2079-9721). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: closed (20 August 2015)

Special Issue Editor

Guest Editor
Dr. Stephen L. Chan
Department of Clinical Oncology, Prince of Wales Hospital, Shatin, HKSAR, China
Phone: 852-26322118
Interests: hepatocellular carcinoma; pancreatic cancer; biliary tract cancer; biomarker; inflammation; targeted therapy

Special Issue Information

Dear Colleagues,

Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide. Drug development for HCC used to be slow due to the relative chemo-refractoriness of the tumor and underlying co-morbid cirrhosis in most patients. Since 2008, clinical trial results on sorafenib have led to development of molecular targeted agents for HCC. For the past 5 years, a number of tyrosine kinase inhibitors have completed phase III testing but all of them have turned out to be negative. These studies persistently reported a median overall survival of 9 to 10 months, indicating that the benefit of an existing panel of targeted agents may have reached a plateau for advanced HCC. To overcome this deadlock, novel agents and concepts are needed from researchers of the HCC research world.

This Special Issue provides an Open Access opportunity to publish research and review articles on targeted therapy for HCC. The focus will be put on a comprehensive review of the current literatures as well as insights into the improvement of success rate of clinical trials on novel agents for the aggressive tumor.

Dr. Stephen L. Chan
Guest Editor

Submission

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diseases is an international peer-reviewed Open Access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. For the first couple of issues the Article Processing Charge (APC) will be waived for well-prepared manuscripts. English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.

Keywords

  • hepatocellular carcinoma
  • sorafenib
  • clinical trial
  • targeted agent
  • cirrhosis
  • hepatitis

Published Papers (12 papers)

Download All Papers
Sort by:
Display options:
Select articles Export citation of selected articles as:
Select/unselect all
Displaying article 1-12
n° 1
by ,  and
Diseases 2016, 4(1), 1; doi:10.3390/diseases4010001
Received: 2 October 2015 / Revised: 3 December 2015 / Accepted: 16 December 2015 / Published: 25 December 2015
Show/Hide Abstract | PDF Full-text (263 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Targeted Therapy of Hepatocellular Carcinoma: Present and Future)
p. 360-381
by , , , , , ,  and
Diseases 2015, 3(4), 360-381; doi:10.3390/diseases3040360
Received: 31 October 2015 / Revised: 19 November 2015 / Accepted: 19 November 2015 / Published: 1 December 2015
Show/Hide Abstract | PDF Full-text (703 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Targeted Therapy of Hepatocellular Carcinoma: Present and Future)
p. 325-340
by , ,  and
Diseases 2015, 3(4), 325-340; doi:10.3390/diseases3040325
Received: 15 September 2015 / Revised: 15 October 2015 / Accepted: 22 October 2015 / Published: 30 October 2015
Show/Hide Abstract | PDF Full-text (784 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Targeted Therapy of Hepatocellular Carcinoma: Present and Future)
p. 294-305
by  and
Diseases 2015, 3(4), 294-305; doi:10.3390/diseases3040294
Received: 20 August 2015 / Revised: 28 September 2015 / Accepted: 20 October 2015 / Published: 28 October 2015
Show/Hide Abstract | PDF Full-text (912 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Targeted Therapy of Hepatocellular Carcinoma: Present and Future)
p. 306-324
by ,  and
Diseases 2015, 3(4), 306-324; doi:10.3390/diseases3040306
Received: 28 August 2015 / Revised: 4 October 2015 / Accepted: 21 October 2015 / Published: 28 October 2015
Show/Hide Abstract | PDF Full-text (886 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Targeted Therapy of Hepatocellular Carcinoma: Present and Future)
p. 260-281
by ,  and
Diseases 2015, 3(4), 260-281; doi:10.3390/diseases3040260
Received: 24 August 2015 / Revised: 11 October 2015 / Accepted: 13 October 2015 / Published: 22 October 2015
Show/Hide Abstract | PDF Full-text (219 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Targeted Therapy of Hepatocellular Carcinoma: Present and Future)
p. 221-252
by ,  and
Diseases 2015, 3(4), 221-252; doi:10.3390/diseases3040221
Received: 9 July 2015 / Revised: 15 September 2015 / Accepted: 21 September 2015 / Published: 29 September 2015
Show/Hide Abstract | PDF Full-text (2042 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Targeted Therapy of Hepatocellular Carcinoma: Present and Future)
abstract graphic
p. 213-220
by , , , , , ,  and
Diseases 2015, 3(3), 213-220; doi:10.3390/diseases3030213
Received: 30 July 2015 / Revised: 10 September 2015 / Accepted: 14 September 2015 / Published: 17 September 2015
Show/Hide Abstract | PDF Full-text (763 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Targeted Therapy of Hepatocellular Carcinoma: Present and Future)
p. 150-158
by , , , , ,  and
Diseases 2015, 3(3), 150-158; doi:10.3390/diseases3030150
Received: 20 May 2015 / Revised: 13 July 2015 / Accepted: 13 July 2015 / Published: 22 July 2015
Show/Hide Abstract | PDF Full-text (671 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Targeted Therapy of Hepatocellular Carcinoma: Present and Future)
p. 68-77
by , , , , , ,  and
Diseases 2015, 3(2), 68-77; doi:10.3390/diseases3020068
Received: 26 March 2015 / Revised: 19 April 2015 / Accepted: 6 May 2015 / Published: 15 May 2015
Show/Hide Abstract | PDF Full-text (776 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Targeted Therapy of Hepatocellular Carcinoma: Present and Future)
p. 226-242
by ,  and
Diseases 2014, 2(3), 226-242; doi:10.3390/diseases2030226
Received: 11 April 2014 / Revised: 10 June 2014 / Accepted: 2 July 2014 / Published: 7 July 2014
Show/Hide Abstract | PDF Full-text (516 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Targeted Therapy of Hepatocellular Carcinoma: Present and Future)
p. 209-225
by , , ,  and
Diseases 2014, 2(3), 209-225; doi:10.3390/diseases2030209
Received: 16 April 2014 / Revised: 24 June 2014 / Accepted: 25 June 2014 / Published: 1 July 2014
Show/Hide Abstract | PDF Full-text (322 KB) | HTML Full-text | XML Full-text
(This article belongs to the Special Issue Targeted Therapy of Hepatocellular Carcinoma: Present and Future)
Select/unselect all
Displaying article 1-12
Select articles Export citation of selected articles as:

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.

Type of Paper: Review 
Title: Radiological Assessment of Antiangiogenic Therapies for Hepatocellular Carcinoma: Which Criteria Apply?
Authors: Mohamed Bouattour 1,*, onorina Bruno 2 and Johanna Wassermann 3
Affiliations:1 Department of Hepatology. Hôpital Beaujon ; 100 Boulevard du Général Leclerc. 92110 Clichy, France 
2 Department of Radiology. Hôpital Beaujon; 100 Boulevard du Général Leclerc. 92110 Clichy, France
3 Department of Medical Oncology. Hôpital Pitié-Salpêtrière; 47-83 boulevard de l'Hôpital
75013 Paris, France
Author to whom correspondence should be addressed; E-Mail: mohamed.bouattour@bjn.aphp.fr; Tel.: +33 1 40 87 55 25; Fax: +33 1 47 39 61 78
Abstract: The sorafenib, an oral multi-tyrosine kinase inhibitor, is currently approved by regulatory agencies as the standard-of-care first-line treatment of advanced hepatocellular carcinoma (HCC). Sorafenib is the first and so far the sole drug that has shown overall survival benefit in patients with advanced HCC in two III trials. The remarkable results obtained by sorafenib are contrasting with objective response rate inferior to 5% according to RECIST criteria. Distinct to standard chemotherapies, low objective response rates were also observed with other antiangiogenic agents tested in HCC. Tumor shrinkage and dimensional changes, usually assessed to define response to cytotoxic drugs based on morphological RECIST criteria, were rarely observed in patients treated with antiangiogenic therapies. Hence, Radiological evaluation of efficacy using standard RECIST criteria is often inappropriate to assess response to targeted agents in HCC patients. Alternatives criteria of response, such as mRECIST, EASL and CHOI criteria have been proposed to assess the direct effect of antianagiogenic therapies in HCC. In this review, we purpose to analyze relevance of these new criteria in clinical practice and their performance to predict response of antiangiogenic therapies for HCC.

Last update: 24 December 2015

Diseases EISSN 2079-9721 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert